Attend the FierceBiotech 3rd Drug Development Forum!
The leading executive-level forum for biotech strategy & networking | Oct 1-3 | Boston
Siemens Healthineers tapped NuVasive as a partner in minimally invasive spine surgery, integrating surgical automation platforms with 3D imaging.
Agilent’s PD-L1 assay was expanded in Europe to help guide first-line Keytruda treatment in urothelial carcinoma.
Boston Scientific is acquiring the remainder of Veniti for $108 million upfront, plus up to $52 million pending approval of its Vici venous stent.
Credence MedSystems received a shot of $12.8 million in financing through a series B round.
Sensyne Health plans to go public with a £60 million listing ($77 million) on the London Stock Exchange on Aug. 17.
Certara said its software supported 95% of the 20 novel FDA approvals from the first half of this year, as the agency aims to modernize its reviews.
Merck and HitGen upsized their licensing agreement to a full discovery collaboration, screening DNA-encoded libraries of billions of small molecules.
Pfizer tapped Antares Pharma to develop a rescue pen for an undisclosed drug, shortly after investing $465 million in a new sterile injectables plant.
Evidation Health raised $30 million in financing, alongside the launch of a platform that digests sensor and behavioral data from real-world settings.
Castle Biosciences’ DecisionDx test improved predictions of melanoma recurrence risk by measuring 31 tumor genes compared to staging alone.